Identification of a new HLA-B*40 allele, HLA-B*4081, in a Chinese individual

Tissue Antigens
H-Y ZouZ-H Deng

Abstract

A novel human leukocyte antigen (HLA)-B*40 allele, officially named B*4081, was identified during routine high-resolution sequence-based typing in a Chinese potential hematopoietic stem cell transplantation donor. The HLA-B*4081 allele shows one nucleotide difference from B*400101 in exon 2 at nucleotide position 124 where G-->C (codon 18 GGG-->CGG) resulting in a coding change, 18Gly is changed to Arg, this is a unique nucleotide change among the HLA class I alleles, suggesting a point mutation mechanism.

References

Jan 10, 2003·Nucleic Acids Research·James RobinsonSteven G E Marsh
Mar 25, 2005·International Journal of Immunogenetics·S G E MarshJ Trowsdale
Mar 25, 2005·Tissue Antigens·S G E MarshJ Trowsdale
Jun 7, 2005·Human Immunology·Steven G E MarshJohn Trowsdale

❮ Previous
Next ❯

Citations

Jun 6, 2009·Tissue Antigens·Steven G E Marsh, UNKNOWN WHO Nomenclature Committee for Factors of the HLA System
Apr 28, 2009·International Journal of Immunogenetics·S G E Marsh
Apr 2, 2010·Tissue Antigens·S G E MarshJ Trowsdale

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.